A clinical study with oral squamous cell carcinomas shows that HLA class I expression is either weak or absent for not stimulation of CD8+ CTL, but there is still no a clear correlation of HLA class I expression loss with a relative proportion of NK cells, indicating that the local factors seem to down-regulate the final outcome of the cytotoxic immune response of NK cells [33]. Indeed, reduced expression of natural cytotoxicity GSK2118436 in vitro receptor, NKG2D ligand UL16 binding protein 1 and Inter-Cellular Adhesion Molecule 1 has been seen on tumor

cells [37, 38], which may specifically prevent NK cell activation. Non-classical HLA-G in inhibition of both CD8+ CTLs and NK cells HLA-G is a non-classical class I antigen, originally detected in trophoblastic cells [39], where it is proposed to suppress maternal immune response against the semi-allogeneic fetus. It binds to the inhibitory receptors Ig-like transcript (ILT) 2, ILT4 or KIR2DL4, resulting in suppression of cytotoxicity of both CD8+ CTL and NK cells [40, 41].

The protective role of HLA-G in carcinoma survival under immune surveillance is MK-0518 chemical structure demonstrated in many studies with patients; in contrast to its null expression in normal epithelial cells and benign adenomas, a high percentage (30-90%) of carcinoma cells expresses HLA-G in a variety of cancerous lesions, and its levels Rebamipide have been found to be significantly associated with clinicopathological features and shorter survival time JPH203 order of patients [42–45]. All these data indicate that carcinoma-expressing HLA-G could be one of important mechanisms for inhibition of both CD8+CTL and NK cell mediated anti-carcinoma immunity. Induction of TIC apoptosis by expression of pro-apoptotic ligands Fas ligand (FasL) FasL binding to death receptor Fas triggers

apoptosis of Fas-expressing cells including TICs. Two patterns of FasL expression on carcinoma cells have been shown by immunohistochemical staining: (1) up-regulation of FasL expression on carcinoma is positively associated with clinicopathological features in patients, shown by that FasL expression is an early event in epithelial cell transformation (adenoma), followed by an increase in the percentage of FasL-expressing carcinoma cells in high-stage or -grade lesions, and the poorer survival of patients with high levels of FasL expression (Table 2); and (2) high levels of FasL expression have been seen as an independent factor for clinicopathological features, indicated by the positive staining of persistent FasL expression regardless of tumor stage, histologic grade, invasion and metastasis in many studies [47, 58–61]. All of these observations suggest that FasL expression is critical for carcinoma survival by induction of TIC apoptosis.